Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and MedImmune, the global biologics research and development arm of AstraZeneca (LSE: AZN, SSE: AZN, NYSE: AZN), today announced that they have entered into a licensing agreement under which Regeneron will use MedImmune’s pyrrolobenzodiazepine (PBD)-based warhead and linker technology to produce antibody- drug conjugates (ADCs) as potential cancer treatments.
{iframe}https://www.twst.com/update/regeneron-pharmaceuticals-inc-regeneron-and-medimmune-enter-into-licensing-agreement-for-the-development-of-antibody-drug-conjugates-to-treat-cancer/{/iframe}